Platelet P2Y12 receptor inhibition by thienopyridines: status and future (Q37579228)

21 August 2017

1 reference

title

Platelet P2Y12 receptor inhibition by thienopyridines: status and future (English)

1 reference

21 August 2017

2

Simona Giubilato

0 references

author name string

Italo Porto

1

1 reference

21 August 2017

Simona Giubilato

2

1 reference

21 August 2017

Giovanni Luigi De Maria

3

1 reference

21 August 2017

Luigi Marzio Biasucci

4

1 reference

21 August 2017

Filippo Crea

5

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Expert Opinion on Investigational Drugs

21 August 2017

published in

1 reference

21 August 2017

volume

18

1 reference

21 August 2017

issue

9

1 reference

21 August 2017

page(s)

1317-1332

1 reference

Platelet activation and atherothrombosis

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Platelet receptors for adenine nucleotides and thromboxane A2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Both the ADP receptors P2Y1 and P2Y12, play a role in controlling shape change in human platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Structure and stereochemistry of the active metabolite of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Gi-dependent and -independent mechanisms downstream of the P2Y12 ADP-receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Studies on the role of the extracellular cysteines and oligomeric structures of the P2Y12 receptor when interacting with antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

How does ticlopidine treatment lower plasma fibrinogen?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Platelet CD40 ligand (CD40L)--subcellular localization, regulation of expression, and inhibition by clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

In vitro effects of clopidogrel on the platelet-subendothelium interaction, platelet thromboxane and endothelial prostacyclin production, and nitric oxide synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Ticlopidine versus aspirin after myocardial infarction (STAMI) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regime

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

The effect of a loading dose (300 mg) of clopidogrel on platelet function in patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Clopidogrel: interactions with the P2Y12 receptor and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Identification of the platelet ADP receptor targeted by antithrombotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Genetic contribution to variable human CYP3A-mediated metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function — a flow cytometry study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Platelet function monitoring in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Advances in antiplatelet therapy: agents in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Intensifying platelet inhibition--navigating between Scylla and Charybdis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a r

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Preclinical and clinical studies with selective reversible direct P2Y12 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903176415

10.1517/13543780903176415

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference